Comparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Voyager Therapeutics, Inc. ?
1
Negative results in Mar 26
- OPERATING CASH FLOW(Y) Lowest at USD -127.99 MM
- ROCE(HY) Lowest at -52.26%
- RAW MATERIAL COST(Y) Grown by 24.32% (YoY)
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 22.67%, its profits have fallen by -84.2%
How much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Voyager Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Voyager Therapeutics, Inc.
20.75%
-0.88
65.63%
S&P 500
20.77%
1.56
13.28%
Quality key factors
Factor
Value
Sales Growth (5y)
-25.09%
EBIT Growth (5y)
-236.94%
EBIT to Interest (avg)
-10.21
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.84
Sales to Capital Employed (avg)
0.42
Tax Ratio
0.82%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
65.74%
ROCE (avg)
0
ROE (avg)
14.16%
Valuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.20
EV to EBIT
-0.36
EV to EBITDA
-0.37
EV to Capital Employed
6.34
EV to Sales
1.17
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1764.04%
ROE (Latest)
-61.06%
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
Technical Movement
5What is working for the Company
NET SALES(HY)
At USD 17.93 MM has Grown at 40.61%
NET PROFIT(HY)
Higher at USD -55.36 MM
-14What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at USD -127.99 MM
ROCE(HY)
Lowest at -52.26%
RAW MATERIAL COST(Y)
Grown by 24.32% (YoY
DEBT-EQUITY RATIO
(HY)
Highest at -61.56 %
NET SALES(Q)
Lowest at USD 2.59 MM
OPERATING PROFIT MARGIN(Q)
Lowest at -1,131.43 %
Here's what is working for Voyager Therapeutics, Inc.
Net Profit
Higher at USD -55.36 MM
than preceding 12 month period ended Mar 2026MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Here's what is not working for Voyager Therapeutics, Inc.
Net Sales
At USD 2.59 MM has Fallen at -74.31%
over average net sales of the previous four periods of USD 10.09 MMMOJO Watch
Near term sales trend is extremely negative
Net Sales (USD MM)
Operating Cash Flow
Lowest at USD -127.99 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Net Sales
Lowest at USD 2.59 MM
in the last five periodsMOJO Watch
Near term sales trend is negative
Net Sales (USD MM)
Operating Profit Margin
Lowest at -1,131.43 %
in the last five periodsMOJO Watch
Company's profit margin has deteriorated
Operating Profit to Sales
Debt-Equity Ratio
Highest at -61.56 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Raw Material Cost
Grown by 24.32% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales






